Mendus

Focus: Mendus is a Swedish cell therapy biotech founded in 2022, focused on immuno-oncology treatments targeting solid and hematologic tumors. The company is publicly traded and operates across multiple oncology indications with a pipeline of dendritic cell and personalized cancer vaccines.

Oncology Gene Therapy Cell Therapy

Profile data last refreshed 10h ago · AI intelligence enriched 3w ago

Funding Stage

PUBLIC

Open Jobs

About Mendus

AI assessmentNot Hiring

No open roles listed right now. Follow Mendus to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

9 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Intuvax

Gastrointestinal Stromal Tumor

PHASE_1

Clinical Trials (1)

NCT02686944A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors

Phase 1

Help build intelligence for Mendus

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage cell therapy platform with 9 active clinical programs spanning gastrointestinal, head/neck, hepatocellular, renal cell, myeloid, and ovarian cancers—significant technical depth for oncology-focused scientists.
Public company status provides liquidity and credibility relative to pre-IPO biotech, reducing funding risk for mid-career joiners.
Based in Stockholm with European regulatory pathway advantage for cell therapy development, offering geographic and regulatory diversification vs. US-centric peers.

Watch Out For

All 9 pipeline programs remain in Phase 1–2 (zero Phase 3 programs); no marketed products means no near-term revenue, extended cash runway pressure, and potential dilution in coming financing rounds.
Zero active job openings (activeJobCount = 0) signals no current hiring; company size unknown (employees = null) and no recent news or hiring department data provided, creating visibility gaps on team stability and growth trajectory.

Generated by Claude from Mendus's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

DCP-001

Ovarian Cancer

PHASE_1

Clinical Trials (1)

NCT04739527Phase 1 Study to Evaluate the Safety, Feasibility and Immunogenicity of an Allogeneic, Cell-based Vaccine (DCP-001) in High Grade Serous Ovarian Cancer Patients After Primary Treatment

Phase 1

COMBIG-DC

Hepatocellular Carcinoma

PHASE_1

Clinical Trials (1)

NCT01974661Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma

Phase 1

Combig-DC

Metastatic Renal Cell Carcinoma

PHASE_1

Clinical Trials (1)

NCT01525017A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Phase 1

ilixadencel

Carcinoma, Squamous Cell of Head and Neck

PHASE_1

Clinical Trials (1)

NCT03735290A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

Phase 1

DCP-001

Acute Myeloid Leukemia (AML)

PHASE_1_2

Clinical Trials (1)

NCT01373515Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia

Phase 1/2

DCP-001

Acute Myeloid Leukemia in Remission

PHASE_2

Clinical Trials (1)

NCT03697707Efficacy and Safety of Immunotherapy With Allogeneic Dendritic Cells, DCP-001, in Patients With Acute Myeloid Leukaemia

Phase 2

Intuvax

Renal Cell Carcinoma, Metastatic

PHASE_2

Clinical Trials (1)

NCT02432846Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC)

Phase 2

vididencel

CML (Chronic Myelogenous Leukemia)

Phase 1

Clinical Trials (1)

NCT07651878Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment

Phase 1